BioSpace News Archive

ABVC BioPharma, Inc. today announced its financial and operating results for the fiscal year ended December 31, 2021.

ValenzaBio, Inc. today announced that its investigational new drug (IND) application for its lead drug candidate, VB421, for the treatment of thyroid eye disease (TED), has been cleared by the U.S. Food and Drug Administration (FDA) for clinical evaluation.

TransCode Therapeutics, Inc. today reported financial results for 2021 and recent business progress.

Venus Concept Inc. today announced it has submitted a 510(k) premarket notification (“510(k)”) to the U.S. Food and Drug Administration (“FDA”), which is intended to obtain a general clinical indication related to the use of its Aime™ next generation robotic technology for tissue excision and skin resurfacing.

Precision Optics Corporation, Inc. announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

West Pharmaceutical Services, Inc. today announced its participation at the 2022 PDA Annual meeting to include sharing the latest in packaging science with scientific talks, moderating session panels and presenting posters, throughout the meeting.

ImmunoGen, Inc. today announced that Dr. Anna Berkenblit, Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel discussion at the upcoming Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for April 14, 2022 from 8:00 – 8:50am ET.

epipole, an emerging provider of world-class handheld fundus cameras, announced the global launch of their new epiCam fundus camera to the US Eye Care market, at the Vision Expo East in New York City.

Adamis Pharmaceuticals Corporation, a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, announced financial results for the year ended December 31, 2021.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, has released its first proof-of-approach white paper (the “White Paper”), establishing the utility of its novel approach to drug discovery utilizing its proprietary platform.